Skip to main navigation
Skip to search
Skip to main content
Albert Einstein College of Medicine Home
Home
Faculty
Departments
Grants
Publications
Prizes
Search by expertise, name or affiliation
Lenalidomide in dlbcl: Are we past the cell of origin?
Mendel Goldfinger
,
Dennis L. Cooper
Oncology
Research output
:
Contribution to journal
›
Article
›
peer-review
5
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Lenalidomide in dlbcl: Are we past the cell of origin?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Lenalidomide
100%
Lymphoma, Large B-Cell, Diffuse
42%
B-Cell Lymphoma
15%
venetoclax
11%
PCI 32765
11%
Rituximab
8%
Vincristine
8%
Prednisone
7%
Combination Drug Therapy
7%
Cyclophosphamide
6%
Doxorubicin
6%
Progression-Free Survival
6%
B-Lymphocytes
5%
Survival Rate
5%
Randomized Controlled Trials
5%
Antibodies
4%
Therapeutics
3%
Pharmaceutical Preparations
3%